News

2021/03/12

【BioXCell】InVivoSIM™ Biosimilar antibody 新品上市


 
照過來!照過來!好康的報給你知道!!!
 
BioXCell新推出 InVivoSIM™系列抗體是研究級生物相似單株抗體(非治療性),是參考目前常使用的單株抗體藥物作為參考藥品(如:Rituximab、Ipilimumab和Nivolumab等),具有與原始藥物級參考藥品相同的活性生物成分,生物相似單株抗體的問市推動了研究單株抗體藥物的生物學效應領域,而無需採購昂貴的藥物級抗體,可大幅減輕研究經費上的負擔。BioXCell的InVivoSIM™抗體皆具有95%以上的純度,且不含防腐劑,穩定劑和載體蛋白。InVivoSIM™抗體皆通過鼠類病原體篩選和低蛋白質聚集,同時也通過免疫印跡進行結合驗證,並保證每毫克內毒素單位少於1EU/mg!

  產品特點: 
  • 純度達95%以上
  • 不含防腐劑、穩定劑和載體蛋白
  • 出廠前經測試不帶有小鼠的病原體
  • 抗體生物活性已通過Immunoblot驗證
  • 可提供1mg、5mg、25mg、50mg跟100mg
  • InVivoSIM™系列抗體僅用於研究目的(RUO),不可用於治療

  產品列表: 
Product Name Application InVivoSIM™ Catalog
InVivoSIM™ anti-human CD20 (Rituximab Biosimilar) FC; ELISA; WB SIM0008
InVivoSIM™ anti-human CTLA-4 (Ipilimumab Biosimilar) CTLA-4 neutralization; FC; ELISA; WB SIM0004
InVivoSIM™ anti-human EGFR (Cetuximab Biosimilar) GFR blockade; ELISA; FC SIM0002
InVivoSIM™ anti-human HER2 (Trastuzumab Biosimilar) FC; ELISA; IHC; WB SIM0005
InVivoSIM™ anti-human PD-1 (Nivolumab Biosimilar) Blocking of PD-1/PD-L signaling; FC; IHC; WB SIM0003
InVivoSIM™ anti-human PD-L1 (Atezolizumab Biosimilar) FC; WB SIM0009
InVivoSIM™ anti-human TNFα (Adalimumab Biosimilar) TNFα neutralization; FC, ELISA; IF; IP; IHC; WB SIM0001
InVivoSIM™ anti-human TNFα (Infliximab Biosimilar) TNFα neutralization; FC; ELISA; WB SIM0006
InVivoSIM™ anti-human VEGF (Bevacizumab Biosimilar) VEGF neutralization; FC; ELISA; IP SIM0007
IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry (requires fluorochrome conjugation)
 
α-human CD20 (Rituximab Biosimilar)
α-human HER2 (Trastuzumab Biosimilar)
 
α-human PD-1 (Nivolumab Biosimilar)
α-human CTLA-4 (Ipilimumab Biosimilar)